| Paramount Bio Sciences, LLC, a global | | | | development, corporate operations, and navigating |
| pharmaceutical development and health care | | | | regulatory pathways. Every new portfolio |
| investment company, was founded and managed | | | | company at Paramount Bio Sciences is built |
| by Dr. Lindsay A. Rosenwald in 1991. The | | | | around intriguing science and commercial potential. |
| company facilitates drug development, scientific | | | | The Portfolio Companies are operated by |
| support and dedicates itself to finding and | | | | Paramount Capital through a dedicated first-class |
| developing novel therapeutic medicines with large | | | | management at the company level, as well as |
| potential. By assessing promising drug candidates | | | | through business and clinical development and |
| worldwide, Paramount has been able to create, | | | | operations specialists working for Paramount in |
| nurture, and support more than 40 life sciences | | | | New York. Chelsea Therapeutics, for example, |
| companies, academic centers, biotechnology and | | | | initially was created or founded by Dr. Rosenwald |
| pharmaceutical firms over the past 19 years, | | | | around a novel anti-folate being developed for the |
| including 20 in the last 48 months. Current | | | | treatment of inflammatory conditions that included |
| Portfolio Companies have over 40 product | | | | rheumatoid arthritis (RA) and psoriasis. Chelsea's |
| candidates advancing through clinical trials. | | | | compound, CH-1504, has demonstrated |
| Unique approach to bio tech investment | | | | superiority in terms of both safety and efficacy |
| Business and product development are just two | | | | over Methotrexate, the current treatment |
| pieces in the Paramount puzzle. An affiliate of | | | | standard for RA, which has been found to elevate |
| Paramount Bio Sciences - Paramount Bio Capital, | | | | liver enzymes in many patients. Paramount Capital |
| Inc., is a FINRA registered broker-dealer that, | | | | licensed this technology from the University of |
| among other activities, raises capital for the | | | | South Alabama and assembled a world-class |
| Paramount Portfolio Companies. It raised over $1 | | | | management team to help optimize its formulation |
| billion for the Portfolio Companies; several times | | | | and advance the development of this and other |
| that amount has been raised for Paramount | | | | compounds. |
| Companies by other entities. While venture capital | | | | Another academic license from Paramount is a |
| and private equity firms tend to be | | | | portfolio of organic arsenic trioxide compounds |
| investment-oriented, Paramount's bias is on the | | | | licensed from the MD Anderson Cancer Center. |
| operational side. It establishes companies from the | | | | This FDA approved compound progressed from |
| ground up, using its own capital and eventually | | | | IND to NDA in about 30 months and this is the |
| funds raised from diverse private and institutional | | | | fastest regulatory approval in the FDA history. |
| investors through Paramount Bio Sciences and | | | | Trisenox, an inorganic alternative of arsenic |
| other banks and broker-dealers on Wall Street. | | | | trioxide, which can product produces cardiac |
| Surely, Paramount's experience in finance and | | | | abnor¬malities at high doses. By contrast with |
| business areas helps make the model attractive | | | | the inorganic version, organic arsenic trioxide does |
| to potential licensors and chief executive officers. | | | | not show evidence of these problems, even |
| With Paramount Capital largely handling accounting, | | | | when used at doses 20 times higher than |
| financial, market analytical and legal functions, | | | | Trisenox. To leverage that advantage, Dr. |
| managers of its Portfolio Companies can focus | | | | Rosenwald founded Ziopharm Oncology to |
| largely on driving drug candidates through the clinic | | | | advance this organic arsenic compound, ZIO-101, |
| and creating value for shareholders, licensors and | | | | to treat cancers, including solid tumors, where |
| the patient community. | | | | mega dosing has proven effective. Ziopharm |
| Infrastructure and Company Building at Paramount | | | | Oncology, as one of many Paramount's portfolio |
| Paramount includes an extensive support | | | | companies, subsequently has in-licensed and is |
| infrastructure with experience in licensing, clinical | | | | developing several other anti-cancer agents. |